Last updated on February 2018

A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants


Brief description of study

The purpose of this study is to evaluate the hemostatic efficacy of andexanet alfa in patients receiving a factor Xa inhibitor who are experiencing an acute major bleed. The safety of andexanet will also be studied.

Clinical Study Identifier: NCT02329327

Contact Investigators or Research Sites near you

Start Over

Patrick Yue, M.D.

Portola Investigational Site
Stoke on Trent, United Kingdom
  Connect »